- Conditions
- Moderate to Severe Gout, Hyperuricemia
- Interventions
- Combination 400, Allopurinol, Combination 600
- Drug
- Lead sponsor
- Nuon Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 24
- States / cities
- La Jolla, California • Santa Maria, California • Washington D.C., District of Columbia + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
- Interventions
- Loncastuximab tesirine, Venetoclax
- Drug
- Lead sponsor
- Paolo Caimi, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Gout
- Interventions
- Lesinurad, Placebo, Allopurinol
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 88
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
- Conditions
- Gout, Hyperuricemia
- Interventions
- Tranilast, Allopurinol, Combination - Tranilast and Allopurinol, 400 mg Allopurinol, High dose combination
- Drug
- Lead sponsor
- Nuon Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
- Conditions
- Cardiovascular Disease
- Interventions
- Febuxostat, Allopurinol
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 6,198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 202
- States / cities
- Decatur, Georgia • Dunwoody, Georgia • Marietta, Georgia + 199 more
- Conditions
- Gout
- Interventions
- Lesinurad
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 151
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Pinson, Alabama + 125 more
- Conditions
- Diabetic Nephropathies, Coronary Artery Disease
- Interventions
- Allopurinol, Placebo
- Drug
- Lead sponsor
- Alessandro Doria
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
- Conditions
- Gout
- Interventions
- Lesinurad, Placebo, Allopurinol
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 607 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 165
- States / cities
- Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 139 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Gout
- Interventions
- Arhalofenate, Allopurinol, Colchicine, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 16
- States / cities
- Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Gout
- Interventions
- RDEA594, Placebo, Allopurinol
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more